BILLERICA, Mass.--(BUSINESS WIRE)--Jan. 26, 2009--Bruker Daltonics announced today the successful installations of its latest ultra-high field 12 Tesla and 15 Tesla (T) FTMS systems in the laboratory of Professor Andre Deelder at the Leiden University Medical Center (LUMC). The 15T FTMS in Leiden will represent the highest field FTMS system in Europe, and the combination of these two, unique systems will be the first of its kind in the world. The extreme mass accuracy and resolving power provided by the 12T and 15T platforms will be used in combination with other mass spectrometry platforms to advance high-throughput proteomics.
At the LUMC, proteomes and metabolomes of different body fluids from various patient cohorts are analyzed. In bottom-up proteomics all proteins are enzymatically digested, yielding an extremely complex mixture of peptides. Multidimensional chromatography combined with 'on-the-fly' MS/MS identification of the eluting peptides in Bruker HCTultra(TM) high-capacity ion trap mass spectrometers is then used to characterize proteins in the mixture. In addition, proteins will be identified in a top-down approach. This analysis of intact proteins allows for complementary sequence coverage. The specificity and identification quality are dramatically enhanced by combining the MS/MS data with the high mass measurement accuracy afforded by FTMS. Since resolution and mass accuracy scale with magnetic field strength, these new high-field FTMS platforms represent a key capability in an unparalleled solution for high-throughput proteomics and metabolomics.
The latest Bruker ESI-Qq-FTMS with a high field magnet features extremely high mass resolving power (> 2,500,000 FWHM at m/z 400 at 15 T), making it ideally suited for analyzing very complex mixtures. This extreme level of performance is accompanied by unsurpassed mass measurement precision (at the ppb level) providing additional specificity for protein identification. The Bruker FTMS provides not only the highest mass resolving power and best mass accuracy available on any mass spectrometer, it also offers the most versatile suite of tools for fragmenting peptides and proteins. Besides the novel Continuous Accumulation of Selected Ions (CASI(TM)) which allows researchers to selectively enrich the signal from a protein or one of its large multiply charged fragments, the Bruker FTMS also includes external collision-cell or internal ICR cell Collision Induced Dissociation (CID), as well as Electron Capture Dissociation (ECD) in the ICR cell. These tools are crucial for determining and localizing important protein post-translational modifications (PTMs), such as phosphorylation or glycosylation.
Professor Andre Deelder commented: "In the last few years, the LUMC has invested significantly in creating a state-of-the-art proteomics infrastructure, and we are very excited by the addition of these world-class instruments to our laboratory. These high-field FTMS systems and their integration into our proteomic workflow will allow a significantly increased capacity for in-depth characterization and quantitative analysis of the large number of samples generally encountered in clinical studies. These platforms will also enable us to identify more proteins with very high quantitative precision."
ABOUT BRUKER DALTONICS
For more information about Bruker Daltonics and Bruker Corporation (NASDAQ: BRKR), please visit www.bdal.com and www.bruker.com.
CONTACT: Bruker Corporation
Investor Relations Contact:
Stacey Desrochers, + 1 978-663-3660 Ext. 1115
ir@bruker.com
or
Media Contact:
Haydar Kustu, + 1 978-439-9899 Ext. 5134
pr@bruker.com
Source: Bruker Corporation